With AU$20 million (US$13.56 million) in new funding, 4dmedical Ltd. is ramping up its commercialization efforts of its four-dimensional lung imaging platform in the U.S.
PERTH, Australia – With a fresh injection of A$28.9 million (US$22.4 million) in grant funding from the Australian government and a capital raise of A$40 million, 4dmedical Ltd. is well on its way to commercializing its first lung imaging product in the U.S. and Australia. 4dmedical’s X-ray velocimetry (XV) technology is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.
-reveals-detailed-maps-of-the-patterns-of-lung-motion-and-pulmonary-function2.webp?height=488&t=1702668104&width=650 "4dmedical’s-Lung-Ventilation-Analysis-Software-(XV-LVAS)-reveals-detailed-maps-of-the-patterns-of-lung-motion-and-pulmonary-function2.jpg")
